Raymond James Resumes Sarepta Therapeutics (SRPT) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
October 11, 2024 5:56 AM EDTBarclays analyst Gena Wang reiterated an Overweight rating and $203.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "Key takeaways. At WMS 2024, SRPT late breaking presentation for Elevidys long-term data from Ph1-3 studies (Study 101, 102, 103, and EMBARK) showed relatively stable left ventricular... More
